The aminoterminal 1-185 domain of human apolipoprotein E suffices for the de novo biogenesis of apoE-containing HDL-like particles in apoA-I deficient mice

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 116-123

  Petropoulou, Peristera A ^a   Gantz, Donald L ^b   Wang, Yanan ^c   Rensen, Patrick C N ^c   Kypreos, Kyriakos E ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ABCA1; Adenovirus mediated gene transfer; ApoA I deficient mice; Apolipoprotein E; De novo biogenesis of HDL; Truncated apoE forms

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIPOPROTEIN SYNTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; HEK293 CELLS; HUMANS; LIPOPROTEINS, HDL; MICE; PROTEIN STRUCTURE, TERTIARY;

EID: 80054990156     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.057     Document Type: Article

References (44)

1. Innerarity T.L., Mahley R.W. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978, 17:1440-1447.
2. Herz J., Willnow T.E. Lipoprotein and receptor interactions in vivo. Curr Opin Lipidol 1995, 6:97-103.
3. Wolf B.B., Lopes M.B., VandenBerg S.R., Gonias S.L. Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am J Pathol 1992, 141:37-42.
4. Kim D.H., Iijima H., Goto K., et al. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem 1996, 271:8373-8380.
5. Takahashi S., Kawarabayasi Y., Nakai T., et al. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A 1992, 89:9252-9256.
6. Mahley R.W., Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999, 10:207-217.
7. Dong L.M., Parkin S., Trakhanov S.D., et al. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol 1996, 3:718-722.
8. Wardell M.R., Brennan S.O., Janus E.D., et al. Apolipoprotein E2-Christchurch (136 ArgcṫSer). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J Clin Invest 1987, 80:483-490.
9. Rall S.C., Newhouse Y.M., Clarke H.R., et al. Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. J Clin Invest 1989, 83:1095-1101.
10. Wardell M.R., Weisgraber K.H., Havekes L.M., Rall S.C. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. J Biol Chem 1989, 264:21205-21210.
11. van den Maagdenberg A.M., de Knijff P., Stalenhoef A.F., et al. Apolipoprotein E*3-Leiden allele results from a partial gene duplication in exon 4. Biochem Biophys Res Commun 1989, 165:851-857.
12. Smit M., de Knijff P., Kooij-Meijs E., et al. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146cṫgln) variant results in a dominant mode of inheritance. J Lipid Res 1990, 31:45-53.
13. Ghiselli G., Schaefer E.J., Gascon P., Breser H.B. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science 1981, 214:1239-1241.
14. Zannis V.I., Just P.W., Breslow J.L. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981, 33:11-24.
15. Kypreos K.E., Li X., Van Dijk K.W., et al. Molecular mechanisms of type III hyperlipoproteinemia: the contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry 2003, 42:9841-9853.
16. Schaefer E.J., Gregg R.E., Ghiselli G., et al. Familial apolipoprotein E deficiency. J Clin Invest 1986, 78:1206-1219.
17. Cladaras C., Hadzopoulou-Cladaras M., Felber B.K., et al. The molecular basis of a familial apoE deficiency. An acceptor splice site mutation in the third intron of the deficient apoE gene. J Biol Chem 1987, 262:2310-2315.
18. Plump A.S., Smith J.D., Hayek T., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353.
19. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468-471.
20. Reddick R.L., Zhang S.H., Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb 1994, 14:141-147.
21. van den Maagdenberg A.M., Hofker M.H., Krimpenfort P.J., et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993, 268:10540-10545.
22. Fazio S., Sanan D.A., Lee Y.L., et al. Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E(Arg 112,Cys142). Arterioscler Thromb 1994, 14:1873-1879.
23. Fazio S., Horie Y., Simonet W.S., et al. Altered lipoprotein metabolism in transgenic mice expressing low levels of a human receptor-binding-defective apolipoprotein E variant. Lipid Res 1994, 35:408-416.
24. van Vlijmen B.J., Van Dijk K.W., van't Hof H.B., et al. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158→Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice. J Biol Chem 1996, 271:30595-30602.
25. Cohn J.S., Tremblay M., Amiot M., et al. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1996, 16:149-159.
26. Chait A., Hazzard W.R., Albers J.J., et al. Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia. Metabolism 1978, 27:1055-1066.
27. Ishibashi S., Perrey S., Chen Z., et al. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem 1996, 271:22422-22427.
28. Havel R.J., Kotite L., Vigne J.L., et al. Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency. J Clin Invest 1980, 66:1351-1362.
29. Huang Y., Liu X.Q., Rall S.C., Mahley R.W. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J Biol Chem 1998, 273:17483-17490.
30. Huang Y., Liu X.Q., Rall S.C., et al. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem 1998, 273:26388-26393.
31. Rensen P.C., van Berkel T.J. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J Biol Chem 1996, 271:14791-14799.
32. Kypreos K.E., Zannis V.I. LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J Lipid Res 2006, 47:521-529.
33. Kypreos K.E., Teusink B., Van Dijk K.W., et al. Analysis of the structure and function relationship of the human apolipoprotein E in vivo, using adenovirus-mediated gene transfer. FASEB J 2001, 15:1598-1600.
34. Kypreos K.E., Morani P., Van Dijk K.W., et al. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice. Biochemistry 2001, 40:6027-6035.
35. Kypreos K.E., Van Dijk K.W., van Der Z.A., et al. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J Biol Chem 2001, 276:19778-19786.
36. Kuipers F., Jong M.C., Lin Y., et al. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J Clin Invest 1997, 100:2915-2922.
37. Kypreos K.E., Karagiannides I., Fotiadou E.H., et al. Mechanisms of obesity and related pathologies: Role of apolipoprotein E in the development of obesity. FEBS J 2009.
38. Kypreos K.E., Zannis V.I. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J 2007, 403:359-367.
39. Hussain M.M., Bucher N.L., Faris B., et al. Tissue-specific posttranslational modification of rat apoE. Synthesis of sialated apoE forms by neonatal rat aortic smooth muscle cells. J Lipid Res 1988, 29:915-923.
40. Li H., Reddick R.L., Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993, 13:1814-1821.
41. Kypreos K.E., Van Dijk K.W., Havekes L.M., Zannis V.I. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia. J Biol Chem 2005, 280:6276-6284.
42. Van Eck M., Herijgers N., Van Dijk K.W., et al. Effect of macrophage-derived mouse ApoE, human ApoE3-Leiden, and human ApoE2 (Arg158→Cys) on cholesterol levels and atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2000, 20:119-127.
43. Forte T.M., Nichols A.V., Krauss R.M., Norum R.A. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. J Clin Invest 1984, 74:1601-1613.
44. Gibson J.C., Rubinstein A., Brown W.V., et al. Apo E-containing lipoproteins in low or high density lipoprotein deficiency. Arteriosclerosis 1985, 5:371-380.